4-Bromo-6-methoxy-2H-pyran-3(6H)-one | 74425-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 4-Bromo-6-methoxy-2H-pyran-3(6H)-one
• 英文别名: 4-bromo-6-methoxy-6H-pyran-3-one；4-Bromo-6methoxy-2H-pyran-3(6H)-one；4-bromo-2-methoxy-2H-pyran-5-one
• CAS: 74425-84-6
• 化学式: C₆H₇BrO₃
• 分子量: 207.024
• InChiKey: MHPVFUMEZDHXFM-UHFFFAOYSA-N

物化性质

• 熔点：
  74-75 °C
• 沸点：
  299.2±40.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  10.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.53
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4-Bromo-6-methoxy-2H-pyran-3(6H)-one 在 三氟乙酸 作用下， 反应 2.0h， 生成 3-羟基-4H-吡喃-4-酮
  参考文献：
  名称：

  Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1‘-Hydroxyalkyl)-3-hydroxypyridin-4-ones:  Novel Iron Chelators with Enhanced pFe³⁺ Values

  摘要：

  The synthesis of a range of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones as bidentate iron(III) chelators with potential for oral administration is described. The pK(a) values of the ligands and the stability constants of their iron(III) complexes have been determined. Results indicate that the introduction of a 1'-hydroxyalkyl group at the 2-position leads to a significant improvement in the pFe(3+) values. Such an effect was found to be greater with the hydroxyethyl substituent than with the hydroxymethyl substituent, particularly in the cases of 1-ethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.4) and 1,6-dimethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.5) where an enhancement on pFe(3+) values in the region of two orders of magnitude is observed, Bs compared with Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (pFe(3+) = 19.4). The ability of these novel 3-hydroxypyridin-4-ones to facilitate the iron excretion in bile was investigated using a [Fe-59]ferritin-loaded rat model. Chelators and prodrug chelators possessing high pFe(3+) values show great promise in their ability to remove iron under in vivo conditions.

  DOI：

  10.1021/jm991080o
• 作为产物：
  描述：

  2,5-二氢-2,5-二甲氧基糠基醇 在 甲酸 、 溴 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-Bromo-6-methoxy-2H-pyran-3(6H)-one
  参考文献：
  名称：

  Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1‘-Hydroxyalkyl)-3-hydroxypyridin-4-ones:  Novel Iron Chelators with Enhanced pFe³⁺ Values

  摘要：

  The synthesis of a range of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones as bidentate iron(III) chelators with potential for oral administration is described. The pK(a) values of the ligands and the stability constants of their iron(III) complexes have been determined. Results indicate that the introduction of a 1'-hydroxyalkyl group at the 2-position leads to a significant improvement in the pFe(3+) values. Such an effect was found to be greater with the hydroxyethyl substituent than with the hydroxymethyl substituent, particularly in the cases of 1-ethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.4) and 1,6-dimethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.5) where an enhancement on pFe(3+) values in the region of two orders of magnitude is observed, Bs compared with Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (pFe(3+) = 19.4). The ability of these novel 3-hydroxypyridin-4-ones to facilitate the iron excretion in bile was investigated using a [Fe-59]ferritin-loaded rat model. Chelators and prodrug chelators possessing high pFe(3+) values show great promise in their ability to remove iron under in vivo conditions.

  DOI：

  10.1021/jm991080o

文献信息

• Orally active iron (III) chelators
  申请人：BTG International Limited

  公开号：US06335353B1

  公开（公告）日：2002-01-01

  A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups —CONH—R5  (i) —CH2NHCO—R5  (ii) —SO2NH—R5  (iii) —CH2NHSO2—R5  (iv) —CR6R6OR7  (v) —CONHCOR5  (viii)  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13 alkyl, aryl and C71-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one.

  提供一种化合物，其为一种新颖的3-羟基吡啶-4-酮化合物，其化学式为I，其中R为氢或在体内代谢中被去除以提供游离羟基化合物的基团，R1为脂肪烃基团或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6芳基氧基或C7-10芳基烷氧基所取代的脂肪烃基团，R3从氢和C1-6烷基中选择；R4从氢、C1-6烷基和如R2所述的基团中选择；其中R2从以下基团中选择：—CONH—R5 (i)—CH2NHCO—R5 (ii)—SO2NH—R5 (iii)—CH2NHSO2—R5 (iv)—CR6R6OR7 (v)—CONHCOR5 (viii) 其中R5从氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基中选择，R6独立选择自氢、C1-13烷基、芳基和C7-13芳基烷基，R7从氢、C1-13烷基、芳基和C7-13芳基烷基中选择，或任何这种化合物的药用盐；但是当R7为氢时，R6不选择自芳基，并且化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。
• Novel orally active iron (III) chelators
  申请人：BTG International Limited.

  公开号：US20020068758A1

  公开（公告）日：2002-06-06

  A novel 3-hydroxypyridinone compound of formula I is provided 1 wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R 1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C 1-6 alkoxy, C 6 -aryloxy or C 7-10 aralkoxy ether thereof, R 3 is selected from hydrogen and C 1-6 alkyl; and R 4 is selected from hydrogen, C 1-6 alkyl and a group as described for R 2 ; characterized in that R 2 is selected from groups (i) —CONH—R 5 (ii) —CH 2 NHCO—R 5 (iii) —SO 2 NH—R 5 (iv) —CH 2 NHSO 2 —R 5 (v) —CR 6 R 6 OR 7 (viii) —CONHCOR 5 wherein R 5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C 1-13 alkyl, aryl and C 7-13 aralkyl, R 6 is independently selected from hydrogen, C 1-13 alkyl, aryl and C 7-13 aralkyl, and R 7 is selected from hydrogen, C 1-13 alkyl, aryl and C 7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R 7 is hydrogen, R 6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one.

  提供了一种新的3-羟基吡啶酮化合物，其化学式为I，其中R为氢或代谢在体内提供自由羟基化合物的基团，R1为脂肪族烃基或被羟基基团或羧酸酯、磺酸酯或其C1-6烷氧基、C6-芳氧基或C7-10芳基烷氧基所取代的脂肪族烃基，R3选自氢和C1-6烷基；R4选自氢、C1-6烷基和如R2所述的基团，其中R2选自以下基团：(i) —CONH—R5(ii) —CH2NHCO—R5(iii) —SO2NH—R5(iv) —CH2NHSO2—R5(v) —CR6R6OR7(viii) —CONHCOR5，其中R5选自氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基，R6独立选自氢、C1-13烷基、芳基和C7-13芳基烷基，R7选自氢、C1-13烷基、芳基和C7-13芳基烷基，或任何这种化合物的药学上可接受的盐，但是当R7为氢时，R6不选自芳基，并且该化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。
• Pyrano [3,2-d]-1,3-dioxin-8 ones
  申请人：BTG International Limited

  公开号：US06506911B2

  公开（公告）日：2003-01-14

  A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6 alkyl; and R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; characterised in that R2 is selected from groups (i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-3 alkyl, aryl and C7-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not l-ethyl-2-(1′hydroxyethyl)-3-hydroxypyridin-4-one.

  提供了一种新型的3-羟基吡啶-4-酮化合物，其化学式为I，其中R是氢或代谢体内去除以提供自由羟基化合物的基团，R1是脂肪烃基或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6-芳氧基或C7-10芳基烷氧基取代的脂肪烃基，R3选自氢和C1-6烷基；R4选自氢、C1-6烷基和R2所述的基团；其特征在于R2选自以下基团(i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5，其中R5选自氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-3烷基、芳基和C7-13芳基烷基，R6独立选自氢、C1-13烷基、芳基和C7-13芳基烷基，R7选自氢、C1-13烷基、芳基和C7-13芳基烷基，或任何这样化合物的药物可接受的盐；但是当R7为氢时，R6不能选自芳基，并且该化合物不是1-乙基-2-(1'羟乙基)-3-羟基吡啶-4-酮。
• Improved procedure for the synthesis of 6-alkoxy-2,3-dihydro-6h-pyran-3-ones (2,3-dideoxy-dl-pent-2-enopyranos-4-uloses). Neat conversion into polyfunctionalized cyclopentenones
  作者：Bernd Mucha、H. Martin、R. Hoffmann

  DOI：10.1016/s0040-4039(01)80725-5

  日期：1989.1
• A ring contraction of 6-alkoxy-2,3-dihydro-6h-pyran-3-ones to polyfunctionalized cyclopentenones
  作者：Hartmuth C. Kolb、H.Martin R. Hoffmann

  DOI：10.1016/s0040-4020(01)87820-0

  日期：1990.1